A detailed history of Natixis Advisors, L.P. transactions in Neogenomics Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 33,982 shares of NEO stock, worth $485,942. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,982
Previous 22,046 54.14%
Holding current value
$485,942
Previous $306,000 63.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$13.4 - $17.73 $159,942 - $211,625
11,936 Added 54.14%
33,982 $501,000
Q2 2024

Aug 01, 2024

SELL
$13.01 - $15.77 $111,886 - $135,622
-8,600 Reduced 28.06%
22,046 $306,000
Q1 2024

Apr 25, 2024

SELL
$14.06 - $16.79 $122,518 - $146,308
-8,714 Reduced 22.14%
30,646 $482,000
Q4 2023

Feb 06, 2024

BUY
$11.67 - $20.73 $233,516 - $414,807
20,010 Added 103.41%
39,360 $636,000
Q3 2023

Nov 13, 2023

SELL
$12.15 - $17.85 $26,875 - $39,484
-2,212 Reduced 10.26%
19,350 $238,000
Q2 2023

Aug 15, 2023

BUY
$14.1 - $19.83 $69,893 - $98,297
4,957 Added 29.85%
21,562 $347,000
Q1 2023

May 11, 2023

BUY
$9.09 - $19.45 $150,939 - $322,967
16,605 New
16,605 $289,000
Q1 2022

May 12, 2022

SELL
$12.15 - $35.28 $156,054 - $453,136
-12,844 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$30.49 - $48.49 $435,519 - $692,631
-14,284 Reduced 52.65%
12,844 $438,000
Q3 2021

Nov 15, 2021

BUY
$41.66 - $52.52 $402,768 - $507,763
9,668 Added 55.37%
27,128 $1.31 Million
Q2 2021

Aug 12, 2021

SELL
$36.62 - $51.69 $101,803 - $143,698
-2,780 Reduced 13.74%
17,460 $789,000
Q1 2021

May 05, 2021

BUY
$41.56 - $59.88 $370,756 - $534,189
8,921 Added 78.81%
20,240 $976,000
Q4 2020

Feb 12, 2021

BUY
$36.08 - $56.47 $408,389 - $639,183
11,319 New
11,319 $609,000

Others Institutions Holding NEO

About NEOGENOMICS INC


  • Ticker NEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 125,796,000
  • Market Cap $1.8B
  • Description
  • NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...
More about NEO
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.